- Former Director of Public and Regulatory Affairs, Quality Assurance, Market Access & Patient Advocacy at Bayer in Spain, Ms. Beatriz Vicén Banzo, joins the Board as a non-executive director
- Ms. Vicén Banzo is a highly regarded and experienced international pharmaceutical regulatory executive, serving as a Member of the Executive Committee for Bayer Pharmaceuticals in Spain since 2008
- The appointment aligns with the Company’s accelerating global ambitions following the acquisition of its Denmark facility in 2021 and subsequent entry into various high-volume European supply agreements
Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce the appointment of Ms. Beatriz Vicén Banzo as non-executive director, effective immediately.
With a decorated career as an expert in regulatory affairs for European pharmaceutical companies, Ms. Vicén Banzo joins LGP having served as Director of Public Affairs and Quality for Bayer in Spain – the Spanish division of the global pharmaceutical leader – since August 2011.
In her senior position at Bayer Pharmaceuticals in Spain, she has been responsible for quality assurance, regulatory affairs, pricing and market access across the business’s divisions, which consist of pharmaceuticals, consumer health, and radiology and intervention.
Prior to working at Bayer Ms. Vicén Banzo held the position of Head of Regulatory Affairs and Permanent Executive Committee Guest at global healthcare company Novartis Pharmaceutical Company for almost a decade, and prior to that held the position of Regulatory Affairs Expert at Ciba-Geigy, a large Swiss-based pharmaceutical and chemicals group that merged with Sandoz to become Novartis.
Commenting on the appointment, Little Green Pharma Chief Executive Officer Fleta Solomon said:
I am very excited to welcome Beatriz to the leadership team at Little Green Pharma. Her experience in international pharmaceutical management and regulation is unmatched and will no doubt be a major asset to the Company as we continue to expand.
In particular, she has detailed knowledge of the development requirements for products in European and international markets, as well as experience executing strategies to build leadership positions in the pharmaceutical industry, highlighted by her time at multinational company Bayer.
Little Green Pharma continues to make a difference to the lives of patients across the globe and it is only fitting that our Board reflects the increasingly international focus of the Company. I look forward to working closely with Beatriz as Little Green Pharma continues to accelerate its activities in the medicinal cannabis industry.Fleta Solomon – CEO
Commenting on her planned contribution to Little Green Pharma, Ms. Vicén Banzo said:
I have worked at an executive level for some of the world’s largest pharmaceutical companies for most of my career, and today am very pleased to be able to lend this knowledge and expertise in support of Little Green Pharma’s ambitions to become the leading medicinal cannabis producer in Europe.Beatriz Vicén Banzo – Non-Executive Director
Ms. Vicén Banzo holds a Degree in Pharmacy as well as an MBA from the University of Barcelona. She also
possesses a Master in European Regulatory Procedures from the Autonomous University of Barcelona as
well as an additional MBA from the globally renowned ESADE Business School.
She has been a lecturer for the Masters program at Madrid-based Professional College Talento
Farmacéutico since 2015 and is fluent in four languages.
The appointment coincides with LGP’s expansion of its operations throughout Europe, following its
acquisition and integration of a large manufacturing facility based in Denmark in 2021.
Subsequent to that acquisition, LGP has executed supply agreements with distributors in countries such
as Germany, Portugal and the UK, as well as being awarded a government medicinal cannabis flower
tender for Italy.
The appointment also aligns with recent encouraging interest by the Spanish Government in the
prescription of medicinal cannabis for certain illnesses. The Spanish market represents an emerging
opportunity for Little Green Pharma, with a large population estimated at just under 50 million people and
an increasing interest in medicinal cannabis.
LGP anticipates increased European and international interest in its cannabis medicines as the Company
contains to establish a greater foothold and the wider European market continues to mature.
For further information please contact: